letrozole has been researched along with Genetic Predisposition in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial." | 6.77 | Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. ( Baudry, K; Berthet, P; Bignon, YJ; Chabbert-Buffet, N; Chiesa, J; Clough, KB; Delaloge, S; Delnatte, C; Dreyfus, H; Dugast, C; Fricker, JP; Gesta, P; Gladieff, L; Lasset, C; Lemonnier, J; Lesur, A; Lortholary, A; Martin, AL; Mijonnet, S; Nogues, C; Prieur, F; Pujol, P; Roca, L; Tennevet, I; This, P; Vennin, P, 2012) |
| "Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial." | 2.77 | Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. ( Baudry, K; Berthet, P; Bignon, YJ; Chabbert-Buffet, N; Chiesa, J; Clough, KB; Delaloge, S; Delnatte, C; Dreyfus, H; Dugast, C; Fricker, JP; Gesta, P; Gladieff, L; Lasset, C; Lemonnier, J; Lesur, A; Lortholary, A; Martin, AL; Mijonnet, S; Nogues, C; Prieur, F; Pujol, P; Roca, L; Tennevet, I; This, P; Vennin, P, 2012) |
| "Melasma is an acquired disorder of pigmentation that presents with asymptomatic symmetric darkening of the face." | 1.46 | Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor. ( Cohen, PR, 2017) |
| "Neoadjuvant therapy in breast cancer has emerged as an important setting for the development of targeted drugs." | 1.37 | Neoadjuvant chemotherapy and targeted therapies: a promising strategy. ( de Azambuja, E; Metzger-Filho, O, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, PR | 1 |
| Metzger-Filho, O | 1 |
| de Azambuja, E | 1 |
| Pujol, P | 1 |
| Lasset, C | 1 |
| Berthet, P | 1 |
| Dugast, C | 1 |
| Delaloge, S | 1 |
| Fricker, JP | 1 |
| Tennevet, I | 1 |
| Chabbert-Buffet, N | 1 |
| This, P | 1 |
| Baudry, K | 1 |
| Lemonnier, J | 1 |
| Roca, L | 1 |
| Mijonnet, S | 1 |
| Gesta, P | 1 |
| Chiesa, J | 1 |
| Dreyfus, H | 1 |
| Vennin, P | 1 |
| Delnatte, C | 1 |
| Bignon, YJ | 1 |
| Lortholary, A | 1 |
| Prieur, F | 1 |
| Gladieff, L | 1 |
| Lesur, A | 1 |
| Clough, KB | 1 |
| Nogues, C | 1 |
| Martin, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation[NCT00673335] | Phase 3 | 170 participants (Actual) | Interventional | 2008-05-31 | Active, not recruiting | ||
| Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation[NCT03667417] | 5,000 participants (Anticipated) | Observational | 1999-10-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for letrozole and Genetic Predisposition
| Article | Year |
|---|---|
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
2 other studies available for letrozole and Genetic Predisposition
| Article | Year |
|---|---|
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genet | 2017 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2011 |